§04§Introductory Remarks.- Nomenclature for Factors of the HLA System 1984.- Joint Reports.- Original Contributions.- Annex.- Index of Authors. §04§45.- HLA-BW46.- HLA-BW47.- HLA-BW48.- HLA-B49.- HLA-Bw50.- HLA-B51 and HLA-Bw52.- HLA-BW53.- HLA-BW54, HLA-BW55, and HLA-BW56.- HLA-BW57.- HLA-BW58.- HLA-Bw59.- HLA-BW60.- HLA-BW61.- HLA-Bw62 and Other Bw6-Associated Variants of B15.- HLA-Bw63 and Other Bw4-Associated Variants of B15.- HLA-Bw67.- HLA-Bw70, HLA-Bw71, and HLA-Bw72.- HLA-Bw73.- HLA-Bw4 and HLA-Bw6.- HLA-CWL.- HLA-CW2.- HLA-CW3.- HLA-CW4.- HLA-CW5.- HLA-CW6.- HLA-CW7.- HLA-CW8.- NEW HLA-C.- HLA-DR1.- HLA-DR2.- HLA-DR3.- HLA-DR4.- HLA-DR5 and Its Subtypes HLA-DRwl 1 and HLA-DRwl2.- HLA-DRW6 and Its Subgroups HLA-DRWL3 and HLA-DRWL4.- HLA-DR7.- HLA-DRW8.- HLA-DRW9.- HLA-DRWL0.- HLA-DRW52.- HLA-DRW53.- New HLA-DR.- HLA-DQWL.- HLA-DQW2.- HLA-DQW3.- Reports on Monoclonal Antibodies.- HLA-A, B, C Monoclonal Antibodies.- HLA-D Region Monoclonal Antibodies.- Special Serology Reports.- HLA-A, B, Interlocus Specificities.- Specificity of The Ninth Workshop Anti la Alloantisera As Assessed by The Direct Binding Assay.- HLA-DR, D §04§Q, and DW Relationships.- HLA-DR, DQ, LB, and TA10 Specificities of Ninth Workshop Homozygous Typing Cells.- Cellular Part: Homozygous Typing Cells (HTC).- Definition of HLA-D with HTC.- Segregation Analysis (HTCS).- First Level Testing of HLA-DR4-Associated New HLA-D Specificities: DWL3 (DB3), DWL4 (LD40), DWL5 (DYT), and DKT2.- First Level Testing of DW6 HTC.- First Level Testing of DW7 HTC.- First Level Testing of DW8 HTC.- First Level Testing of HLA-D "Blank" HTC.- DNA Restriction Fragment Length Polymorphism of Some Ninth Workshop Homozygous Typing Cells Using a cDNA Probe Specific for DRß.- Cellular Part: Primed Lymphocyte Typing (PLT).- Genetic Analysis of HLA-D Region Products Defined by PLT.- Segregation Analysis of PLT Reagents in Families.- Median Stabilization of PLT Data for the Central Workshop Analysis.- Origin and Expansion of SB (DP)-Specific Reagents Characterized in the Ninth International Workshop.- Cellular Part: Cell-Mediated Lympholysis (CML).- CML: A Method §04§ for Cellular Typing.- Complement Polymorphisms.- The Second Complement Component, C2, in the Ninth Workshop.- Properdin Factor B.- C4 Polymorphism.- Genetics of HLA.- Analysis of MHC Recombinant Families.- Linkage Between HLA-A, C, B, Bf and DR Alleles: Haplotype Study of Healthy Families by Factorial Correspondence Analysis.- The Nature of Selection in the HLA Region Based on Population Data From the Ninth Workshop.- Population Analysis on the Basis of Deduced Haplotypes from Random Families.- Ninth International Histocompatibility Workshop Renal Transplant Study.- Disease Reports.- Insulin-Dependent Diabetes Mellitus.- HLA-DR3 and DR7-Negative Celiac Disease.- Leprosy.- Juvenile Chronic Arthritis, Pauciarticular Type.- A Family Study of Gold-Induced Nephropathy in Patients with Rheumatoid Arthritis.- Rheumatoid Arthritis.- D-Penicillamine-Induced Myasthenia Gravis.- HLA-B27-Negative Ankylosing Spondylitis.- Scleroderma: Possible Association with the C4 System - A Progress Repor §04§t.- Beh?et's Disease.- Kawasaki Disease (Mucocutaneous Lymph Node Syndrome).- Classical and AIDS Kaposi's Sarcoma.- HLA and Familial Malignant Melanoma.- Hodgkin's Disease.- Original Contributions.- Serology.- Human Histocompatibility Antigens in Malignant Tumors of Nonlymphoid Origin.- B27 Subtypes.- Segregation of DQ and DR: "Exceptions to the Rule".- Characterization of a New Subset of B Cell Alloantigens.- Serologic Detection of New Polymorphisms on DQ Molecules Distinct from the DQw1, 2, and 3 Specificities.- Analysis of 9W Antisera Detecting DR4- and DR2-Associated Epitopes by Use of Anti-idiotypic Antibodies.- The HLA-D Region: Serology, Structure, Tissue Distribution, and Function of Human Class II Molecules and Their Antigenic Determinants.- Definition of MCI, a Novel HLA Determinant Associated with DR1 and DR4.- A Monoclonal Antibody (GH-3): "Non-orthodox" Anti-HLA-A3 or A11 Induced by a Lymph Node Extract from a Hodgkin's Disease Patient.- Enhancing Monoclonal Antibodie
